Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes

Ann Hematol. 2009 Dec;88(12):1261-2. doi: 10.1007/s00277-009-0749-z. Epub 2009 May 9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • Bone Marrow Diseases / drug therapy*
  • Bone Marrow Diseases / physiopathology
  • Clinical Trials, Phase II as Topic
  • Ganciclovir / analogs & derivatives*
  • Ganciclovir / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Recurrence
  • Syndrome
  • Valganciclovir

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Antiviral Agents
  • Immunosuppressive Agents
  • Alemtuzumab
  • Valganciclovir
  • Ganciclovir